Skip to main content

Table 5 Number of relapses in each study group during the 12-month study period

From: The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study

Number of relapses

Groups

Study group

Number (%)

Control group

Number (%)

0

18 (90)

0 (0)

1

2 (10)

11 (36.6)

2

0 (0)

19 (63.3)